💊 The pHLIP LNP platform uses pH-low insertion peptides to enhance the delivery of therapeutic molecules.
🚀 CordenPharma aims to leverage this technology to expand its capabilities in drug development and delivery.
🤝 This partnership will help CordenPharma provide innovative solutions to the global biotechnology industry.
Introduction:
CordenPharma, a pharmaceutical contract development and manufacturing organization (CDMO), has signed an agreement with pHLIP, a biotechnology company, to develop a lipid nanoparticle (LNP) platform. This platform is designed to enhance the delivery of therapeutic RNA molecules to target cells. The partnership aims to leverage CordenPharma’s expertise in manufacturing and process development with pHLIP’s proprietary pH Low Insertion Peptide (pHLIP) technology.
- The partnership between CordenPharma and pHLIP aims to develop a lipid nanoparticle (LNP) platform for the delivery of therapeutic RNA molecules.
- The pHLIP technology, developed by pHLIP, is a pH-responsive peptide that can deliver payloads directly into target cells.
- The LNP platform will be optimized for the delivery of RNA-based therapeutics, such as mRNA and siRNA, which have shown great potential in various disease areas.
- CordenPharma will utilize its expertise in manufacturing and process development to scale up the production of the LNP platform.
- This partnership has the potential to revolutionize the field of RNA therapeutics by improving the delivery of these molecules and enabling the development of new treatments for various diseases.
Conclusion:
CordenPharma’s partnership with pHLIP to develop a lipid nanoparticle (LNP) platform for the delivery of therapeutic RNA molecules holds great promise for the field of RNA therapeutics. The pHLIP technology’s pH-responsive peptide can enhance the delivery of RNA molecules to target cells, opening up new possibilities for the treatment of various diseases. With CordenPharma’s expertise in manufacturing and process development, this partnership has the potential to accelerate the development and commercialization of RNA-based therapeutics and improve patient outcomes.
